新诊断的多发性骨髓瘤患者的治疗模式
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
作者信息
Greipp Philip
机构信息
Hematologic Malignancies Program, The Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Semin Hematol. 2005 Oct;42(4 Suppl 4):S16-21. doi: 10.1053/j.seminhematol.2005.10.002.
The management of newly diagnosed multiple myeloma is currently being revolutionized by the emergence of novel therapeutic agents. Thalidomide, the thalidomide analogue lenalidomide, and the proteasome inhibitor bortezomib each have potential roles to play in the initial therapy of myeloma that are supported by encouraging clinical trials results. While evaluation for stem cell transplantation (SCT) remains a part of the algorithm for management of the newly diagnosed patient, these drugs offer improved options for induction before, and possibly maintenance after, SCT. For the patient who is not a candidate for SCT the armamentarium for management has been significantly expanded. This review will summarize currently available data regarding these exciting agents and will describe therapeutic strategies currently on the horizon.
新型治疗药物的出现正在彻底改变新诊断多发性骨髓瘤的治疗方式。沙利度胺、沙利度胺类似物来那度胺以及蛋白酶体抑制剂硼替佐米在骨髓瘤初始治疗中均具有潜在作用，令人鼓舞的临床试验结果为其提供了支持。虽然干细胞移植（SCT）评估仍是新诊断患者治疗方案的一部分，但这些药物为SCT前的诱导治疗以及可能的SCT后的维持治疗提供了更好的选择。对于不适合进行SCT的患者，治疗手段已显著增加。本综述将总结有关这些令人振奋的药物的现有数据，并描述目前正在探索的治疗策略。
Zotero 插件